Men with HIV who are on testosterone therapy appear to have an elevated risk for significant coronary artery calcium progression (CAC) vs those who are not on it, according to a study released at CROI 20.
A once-weekly tuberculosis (TB) prevention regimen of isoniazid 900 mg and rifapentine 900 mg given for 3 months (3HP) resulted in higher treatment completion rates vs isoniazid daily for 6 months (6H) in patients with HIV receiving antiretroviral therapy (ART), a study released at CROI 2020 has shown.
The combination of dolutegravir (DTG)/emtricitabine (FTC)/tenofovir alafenamide fumarate (TAF) has superior virologic efficacy and safety compared with an efavirenz (EFV)/FTC/tenofovir disoproxil fumarate (TDF) combination in pregnant women living with HIV (WLHIV), results of the IMPAACT 2010/VESTED* trial showed.
The second HIV patient to successfully undergo stem cell transplantation is still in remission, a good 30 months after stopping antiretroviral therapy (ART) — raising hope that curing HIV is a possibility.
The gap in overall life expectancy between people with HIV (PWH) and those without HIV has narrowed over time, particularly among optimally treated PWH. However, PWH still have fewer comorbidity-free years than those without HIV, according to a study presented at CROI 2020.
Children with HIV (HIV+) who switched to efavirenz had higher bone mass even after 4 years of switching compared with those who remained on an antiretroviral therapy (ART) regimen comprising lopinavir and ritonavir, according to data presented at CROI 2020.
A long-acting (LA) injectable therapeutic regimen comprising the integrase strand-transfer inhibitor cabotegravir and the nonnucleoside reverse-transcriptase inhibitor rilpivirine shows therapeutic potential over an oral antiretroviral therapy (ART) regimen in adults with HIV-1, according to the week 96 results of the phase III FLAIR* trial.
Every-two-month injections of the long-acting cabotegravir + rilpivirine were noninferior to once-monthly injections for virologic suppression at 48 weeks in people living with HIV*, according to the ATLAS-2M** study presented at CROI 2020 — thus providing a potential option with more convenient dosing.
Obesity does not appear to be strongly correlated with an increased risk for febrile neutropaenia during levofloxacin prophylaxis in patients with haematological malignancies receiving intermediate-risk myelosuppressive chemotherapy, suggests a study.
Initiation or switch to the single-tablet regimen of bictegravir/emtricitabine/tenofovir alafenamide (TAF) led to low HIV-1 RNA viral load in people living with HIV (PLHIV), according to the BICSTaR study presented at HIV Glasgow 2020.
Use of corticosteroids appears to be an effective treatment for paediatric drug reaction with eosinophilia and systemic symptoms (DRESS), suggest the results of a recent study. In severe cases, corticosteroids used in conjunction with intravenous immunoglobulin result in fast clinical improvement.
Patients with chronic obstructive pulmonary disease (COPD) seem to benefit from using chlorhexidine oral rinses twice daily as shown by the reduction in oral and sputum microbiota alpha diversity and by clinically significant improvements in COPD symptoms, according to a study presented at ID Week 2020.